Results 121 to 130 of about 12,486 (248)

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real‐World Data

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bilirubin is a breakdown product of erythrocytes and plays a crucial role in elimination of heme‐containing proteins. After its synthesis in the reticuloendothelial system, unconjugated bilirubin is released into plasma and taken up into the liver.
Ahenk Zeynep Sayin, Lars Kuepfer
wiley   +1 more source

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis. [PDF]

Front Pharmacol, 2023
Reali F, Fochesato A, Kaddi C, Visintainer R, Watson S, Levi M, Dartois V, Azer K, Marchetti L.   +8 more
europepmc   +1 more source

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against Streptococcus suis

Frontiers in Pharmacology
Introduction: Streptococcus suis (S. suis) is a zoonotic pathogen threatening public health. Aditoprim (ADP), a novel veterinary medicine, exhibits an antibacterial effect against S. suis.
Kun Mi, Kun Mi, Lei Sun, Lei Sun, Lan Zhang, Lan Zhang, Aoran Tang, Aoran Tang, Xiaoyuan Tian, Xiaoyuan Tian, Yixuan Hou, Yixuan Hou, Lingling Sun, Lingli Huang, Lingli Huang, Lingli Huang   +15 more
doaj   +1 more source

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment

Frontiers in Pharmacology
IntroductionAll cosmetic ingredients must be evaluated for their safety to consumers. In the absence of in vivo data, systemic concentrations of ingredients can be predicted using Physiologically based Pharmacokinetic (PBPK) models.
A. Najjar, D. Lange, C. Géniès, J. Kuehnl, A. Zifle, C. Jacques, E. Fabian, N. Hewitt, A. Schepky   +8 more
doaj   +1 more source

Quantitative Evaluation of Model‐Informed Drug Development Implementation in China's Approved Innovative Drugs: From Policy to Practice (2018–2024)

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Model‐informed drug development (MIDD) has emerged as a cornerstone paradigm in global pharmaceutical innovation. Historically underutilized in China, MIDD methodologies gained momentum following the National Medical Products Administration's (NMPA) 2020 release of the Model‐Informed Drug Development Technical Guideline, which was subsequently
Jian Li, Zhenlei Wang, Chunmin Wei, Ruirui He, Qingyu Yao   +4 more
wiley   +1 more source

The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant. [PDF]

Pharmaceutics, 2023
Saldanha L, Vale N.
europepmc   +1 more source

Integrated PBPK modelling for PFOA exposure and risk assessment

Environmental Research
Per- and polyfluoroalkyl substances (PFASs) pose significant public health concerns due to their environmental persistence, bioaccumulation, and ubiquitous presence in human biomonitoring (HBM) data, despite regulatory restrictions. This study establishes a deterministic pharmacokinetic model for perfluorooctanoic acid (PFOA), enabling the estimation ...
Achilleas Karakoltzidis, Spyros P. Karakitsios, Catherine Gabriel, Dimosthenis Α. Sarigiannis   +3 more
openaire   +2 more sources

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim, Ingrid F. Metzger, Jessica Bo Li Lu, Todd C. Skaar, Zeruesenay Desta   +4 more
wiley   +1 more source

Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Dicloxacillin and flucloxacillin are β‐lactamase‐resistant penicillin antibiotics that have been in clinical use for over 50 years. While both antibiotics are known to induce cytochrome P450 enzymes, there is limited information available regarding their interactions with drug transporters.
Noora Sjöstedt, Ogochukwu U. Amaeze, Jeroen J. M. W. van den Heuvel, Tore B. Stage, Jan B. Koenderink, Nina Isoherranen, Heidi Kidron, Erkka Järvinen   +7 more
wiley   +1 more source

A permeability- and perfusion-based PBPK model for improved prediction of concentration-time profiles. [PDF]

Clin Transl Sci, 2022
Korzekwa K, Radice C, Nagar S.
europepmc   +1 more source